“Fast but not so furious”: A condensed step‐up dosing schedule of teclistamab for relapsed/refractory multiple myeloma

Abstract Teclistamab is a B‐cell maturation antigen (BCMA)‐directed bispecific T‐cell engager approved for relapsed‐refractory multiple myeloma (RRMM). Cytokine release syndrome (CRS) and Immune effector cell‐associated neurotoxicity syndrome (ICANS) are well‐documented treatment ‐related adverse ev...

Olles dieđut

Bibliográfalaš dieđut

Váldodahkkit:	Kevin C. Graf, James A Davis, Alyssa Cendagorta, Katelynn Granger, Kelly J. Gaffney, Kimberly Green, Brian T Hess, Hamza Hashmi
Materiálatiipa:	Artigo
Giella:	Inglês
Almmustuhtton:	Wiley 2024-08-01
Ráidu:	eJHaem
Fáttát:	immunotherapy multiple myeloma myeloma therapy
Liŋkkat:	https://doi.org/10.1002/jha2.906
Fáddágilkorat:	Lasit fáddágilkoriid Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!